WORCESTER, Mass., Dec. 23, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that Lebanon’s Ministry of Public Health has approved Generex Oral-lyn, the Company’s proprietary oral insulin spray product, for importation, marketing, distribution, and commercial sale in the Republic of Lebanon for the treatment of adults and children with Type-1 or Type-2 diabetes mellitus.
